Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension

Area of Science:

• Pulmonary Hypertension Research
• Vascular Biology
• Pharmacology

Background:

• Prostacyclin (PGI2) is clinically used for severe pulmonary hypertension (PH).
• PGI2's mechanism in PH, potentially involving anti-proliferative effects via the PGI2 receptor (PGIR), remains unclear.
• Understanding PGI2's effects on pulmonary vascular remodeling is crucial.

Purpose of the Study:

• To investigate the morphological changes in lung tissue associated with PGI2 treatment in PH patients.
• To evaluate the impact of PGI2 therapy on pulmonary vascular remodeling.
• To assess differences in PGIR expression between PGI2-treated and untreated PH patients.

Main Methods:

• Histopathologic and morphometric analysis of explanted lung tissues from PGI2-treated (n=9) and untreated (n=11) PH patients.
• Immunohistochemical staining to evaluate PGIR expression.
• Comparison of vascular wall thickness (intima, media, adventitia) and plexiform lesion density.

Main Results:

• PGI2-treated patients exhibited significantly more bronchial/perivascular inflammation and alveolar edema compared to controls.
• Morphometric analysis showed no significant differences in vascular wall thickness or plexiform lesion density.
• Immunohistochemistry revealed no notable difference in PGIR expression between the groups.

Conclusions:

• PGI2 therapy in PH patients is associated with increased pulmonary edema and inflammation.
• No morphological evidence of altered vascular remodeling or changes in PGIR expression was observed post-PGI2 therapy.
• Further research is needed to fully elucidate PGI2's therapeutic mechanisms in pulmonary hypertension.